You are on page 1of 1

Cinqair (reslizumab); Teva Pharmaceuticals; For the treatment of severe

asthma, Approved March 2016


Nucala (mepolizumab); GlaxoSmithKline; For the treatment of severe asthma
with an eosinophilic phenotype, Approved November 2015
Arnuity Ellipta (fluticasone furoate inhalation powder); GlaxoSmithKline; For
the treatment of asthma, Approved August 2014

You might also like